[1] Medina-Caliz I, Robles-Diaz M, Garcia-Mu oz B, et al. Spanish DILI Registry. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. J Hepatol, 2016, 65:532-542.
[2] Aithal GP, Watkins PB, Andrade RJ. Case definition and phenotype standardization in drug-induced liver injury. Clin Ppharmacol Ther, 2011, 89:806-815.
[3] Seeff LB. Drug-induced chronic liver disease, with emphasis on chronic active hepatitis. Semin Liver Dis, 1981, 1:104-115.
[4] Benichou C. Criteria of drug-induced liver disorders. Report of an International Consensus Meeting. J Hepatol, 1990, 11: 272-276.
[5] Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology, 2006, 44: 1581-1588.
[6] Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct. Drug Saf, 2009, 32: 55-68.
[7] Chalasani N, Fontana RJ, Bonkovsky HL, et al. Drug Induced Liver Injury Network (DILIN). Causes, clinical features and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology, 2008, 135: 1924-1934.
[8] Fontana RJ, Hayashi PH, Gu J, et al. DILIN Network. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology, 2014, 147: 96-108.
[9] Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol, 2014,109:950-966.
[10] 中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南. 肝脏, 2015, 20: 750-767.
[11] Borraz Y. Would it be desirable to modify the cut-off point for definition of chronicity in drug-induced liver injury (DILI) (abstract). Hepatology, 2010, 52: 457A.
[12] Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut, 1999, 44: 731-735.
[13] Fontana RJ, Hayashi PH, Barnhart H, et al. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. Am J Gastroenterol, 2015, 110: 1450-1459.
[14] Lucena MI, Kaplowitz N, Hallal H, et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol, 2011, 55: 820-827. |
